Stevanato Group S.p.A. (STVN)
Stevanato Group S.p.A. (STVN) Q1 2025 Earnings Call Transcript
Stevanato Group S.p.A. (NYSE:STVN ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Lisa Miles - SVP & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Paul Knight - KeyBanc Michael Ryskin - Bank of America David Windley - Jefferies Tejas Savant - Morgan Stanley Steven McLaurin Etoch - Stephens Inc Patrick Donnelly - Citi Doug Schenkel - Wolfe Research Operator Good afternoon.
Stevanato Group (STVN) Q1 Earnings and Revenues Top Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.09 per share a year ago.
Stevanato: Ramping Syringe Demand, Buy Confirmed
Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues. Investments in expanding facilities in Latina and Fishers aim to meet rising product demand, and a significant sales increase is expected. Supportive CAPEX investment in different GEO provides downside protection in case of tariff war.
Stevanato Group S.p.A. (STVN) Q4 2024 Earnings Call Transcript
Stevanato Group S.p.A. (NYSE:STVN ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Lisa Miles - SVP, IR Franco Stevanato - Chairman and CEO Marco Dal Lago - CFO Conference Call Participants Michael Ryskin - Bank of America Matt Larew - William Blair Patrick Donnelly - Citi David Windley - Jefferies Pete Lukas - CJS Securities Anna Snopkowski - KeyBanc Tejas Savant - Morgan Stanley Doug Schenkel - Wolfe Research Operator Good afternoon.
Stevanato Group (STVN) Meets Q4 Earnings Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.20 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.19 per share a year ago.
Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin improvement thanks to high-value solutions and new facilities ramp-up. Long-term growth remains strong, and Stevanato's economic moat remains intact. Looking ahead, we decided to maintain our buy rating target.
Stevanato Group S.p.A. (STVN) Q3 2024 Earnings Call Transcript
Stevanato Group S.p.A. (NYSE:STVN ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Lisa Miles - Senior Vice President & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Larry Solow - CJS Securities Patrick Donnelly - Citi Jacob Johnson - Stephens Dave Windley - Jefferies Paul Knight - KeyBanc Capital Markets Dan Leonard - UBS Curtis Moiles - BNP Paribas Exane Operator Good afternoon.
Stevanato Group (STVN) Q3 Earnings Match Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.16 per share a year ago.
Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stevanato Group S.p.A. (STVN) Q2 2024 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q2 2024 Earnings Call Transcript
Stevanato Group (STVN) Q2 Earnings Match Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.15 per share a year ago.
Stevanato Group S.p.A. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - STVN
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
